Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Sign Up to like & getrecommendations! Published in 2019 at "Fertility and sterility"
DOI: 10.1016/j.fertnstert.2019.07.013
Abstract: OBJECTIVE To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid-associated pain. DESIGN Phase 3, multicenter, randomized, double-blind, placebo-controlled study. SETTING Centers. PATIENT(S) Premenopausal Japanese women… read more here.
Keywords: relugolix; treatment; study; oral gonadotropin ... See more keywords